Dare Bioscience Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
3analysts covering
FY EPS (est.)
-$0.43next fiscal year
Monitoring Framework
Key Performance Indicators
Direct Product Revenue Quarterly0.0Target: Commence recording product revenue from Flora Sync LF5 in June 2026 and DARE to PLAY in Q3 2026
Ovaprene Phase III Clinical Trial Enrollment QuarterlyTarget: Complete enrollment in 2026 to achieve at least 2,500 menstrual cycles of exposure
DARE-HPV Phase II Clinical Study Progress QuarterlyTarget: Initiate and advance Phase II study in 2026 utilizing non-dilutive ARPA-H funding
Watch Items
- Going Concern Risk and Cash RunwayTrigger: Working capital falling below $0.5 million or failure to secure additional non-dilutive/dilutive financingAction: Evaluate alternative financing options, including further Regulation A closings, strategic collaborations, or equity line drawdowns under the Lincoln Park agreement.
- State Licensing and Fulfillment Preparations for DARE to PLAYTrigger: Delays in Bravado completing state licensing and fulfillment preparations beyond Summer 2026Action: Assess commercial channel readiness and coordinate with compounding pharmacy partners to resolve regulatory bottlenecks.
Research as of 20 Jun 2026